Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxatomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 1.00 |
| ▸ | P2RX7 | Q99572 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxatomide SCHEMBL28824 | 1.00 | P2RX7 (1.00) | P2RX7LMNAMEN1MLNRNR1I2 | |
| Oxatomide SCHEMBL8693571 | 0.99 | P2RX7 (0.98) | P2RX7LMNAMEN1MLNRNR1I2 | |
| Oxatomide SCHEMBL11472510 | 0.99 | P2RX7 (0.98) | P2RX7LMNAMEN1MLNRNR1I2 | |
| Oxatomide SCHEMBL7558760 | 0.99 | P2RX7 (0.98) | P2RX7LMNAMEN1MLNRNR1I2 | |
| Oxatomide SCHEMBL8693540 | 0.99 | P2RX7 (0.98) | P2RX7LMNAMEN1MLNRNR1I2 | |
| Oxatomide SCHEMBL11199692 | 0.98 | P2RX7 (0.95) | P2RX7LMNAMEN1MLNRNR1I2 | |
| SCHEMBL11198903 | 0.98 | P2RX7 (1.00) | P2RX7LMNAMEN1MLNRNR1I2 | |
| Water SCHEMBL11197270 | 0.96 | P2RX7 (0.98) | P2RX7LMNAMEN1MLNRNR1I2 | |
| SCHEMBL11195898 | 0.96 | P2RX7 (1.00) | P2RX7LMNAMEN1MLNRNR1I2 | |
| Water SCHEMBL11197269 | 0.96 | P2RX7 (0.98) | P2RX7LMNAMEN1MLNRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119372283-B | Cholinesterase determination reagent and application thereof | 中生北控生物科技股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-119372283-A | Cholinesterase determination reagent and application thereof | 中生北控生物科技股份有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-119354667-A | Total bilirubin determination reagent capable of detecting heparin anticoagulated plasma | 中生北控生物科技股份有限公司 | 2025-01-24 | — | — | CN | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| CN-112710609-B | Anti-chyle interference uric acid determination kit | 中生北控生物科技股份有限公司 | 2022-03-04 | — | — | CN | claimed |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | disclosed |
| US-12472241-B2 | Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| EP-4167940-B1 | AGENT FOR DYEING KERATINOUS FIBERS CONTAINING CERTAIN NONIONIC EMULSIFIERS, PIGMENTS AND AMINOSILICONES | HENKEL AG & CO KGAA (DE) | 2025-04-09 | — | — | EP | disclosed |
| CN-119372283-B | Cholinesterase determination reagent and application thereof | 中生北控生物科技股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119372283-A | Cholinesterase determination reagent and application thereof | 中生北控生物科技股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-119354667-A | Total bilirubin determination reagent capable of detecting heparin anticoagulated plasma | 中生北控生物科技股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-3474953-B1 | SUBSTANCE MIXTURE CONTAINING GLYCOSAMINOGLYCAN, METHOD FOR PRODUCING SAME AND USE OF SAME | FACH DR CHRISTIAN (DE) | 2022-11-16 | — | — | EP | disclosed |
| CN-115135647-A | Pesticidally active fused bicyclic heteroaromatic amino compounds | 先正达农作物保护股份公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-114630825-A | Pesticidally active fused bicyclic heteroaromatic compounds | 先正达农作物保护股份公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2022119431-A1 | PHARMACEUTICAL COMPOSITION HAVING AN ANALGAESIC AND AN ANTIHISTAMINE FOR TREATING RESPIRATORY DISEASES | LABORATORIOS SILANES S.A. DE C.V. (MX) | 2022-06-09 | — | — | WO | disclosed |
| CN-114466658-A | Orally delivered therapeutic compositions and uses thereof | 沈海发 | 2022-05-10 | — | — | CN | disclosed |
| CN-110418646-B | Plant extract for preventing and treating alopecia | 朱利亚尼股份公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-112710656-B | Kit for determining glucose content and application thereof | 中生北控生物科技股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-112710609-B | Anti-chyle interference uric acid determination kit | 中生北控生物科技股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | ALOX15, ALOX15B, ALOX5 | HRH1 559/4885P2RX7 1107/4885LMNA 1753/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | HRH1 3405/4885P2RX7 4606/4885LMNA 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.